Hangzhou Jinjiang Group

Hangzhou Jinjiang Group is a large-scale private Chinese conglomerate headquartered in Hangzhou, with a diverse business portfolio that includes environmental protection, non-ferrous metals, chemicals, and healthcare. Founded in 1983, the group has become a significant player in the life sciences sector primarily through its ownership and support of Zhejiang Kanglaite Pharmaceutical. This subsidiary is renowned for developing Kanglaite Injection, a botanical-derived oncology drug that has successfully entered clinical trials in both China and the United States. The group's healthcare division also encompasses medical services and health management, reflecting a strategic commitment to the Big Health industry. Additionally, the group leverages its extensive chemical manufacturing infrastructure to produce pharmaceutical intermediates.